Apellis Pharmaceuticals (APLS) Financials

$17.49 +0.12 (+0.69%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$17.53 +0.04 (+0.25%)

As of 07:08 AM Eastern

Annual Income Statements for Apellis Pharmaceuticals

This table shows Apellis Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-47	-27	-51	-128	-305	-345	-748	-651	-529	-198
Consolidated Net Income / (Loss)	-47	-27	-51	-128	-305	-345	-746	-652	-529	-198
Net Income / (Loss) Continuing Operations	-47	-27	-51	-128	-305	-345	-746	-652	-529	-198
Total Pre-Tax Income	-47	-27	-51	-128	-305	-343	-746	-652	-526	-197
Total Operating Income	-47	-27	-51	-128	-288	-214	-536	-595	-517	-165
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	251	67	75	397	781
Total Revenue	0.00	0.00	0.00	0.00	0.00	251	67	75	397	781
Operating Revenue	-	-	-	0.00	0.00	251	67	75	397	781
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	47	27	51	128	288	464	603	670	914	946
Selling, General & Admin Expense	6.36	4.30	10	23	67	139	177	277	501	501
Research & Development Expense	40	23	40	105	221	300	346	387	354	328
Other Operating Expenses / (Income)	-	-	-	-	0.00	25	75	0.00	59	118
Total Other Income / (Expense), net	0.06	0.16	-0.24	0.42	-17	-129	-210	-57	-9.38	-32
Interest Expense	-	0.00	0.37	2.51	6.79	30	13	33	30	40
Interest & Investment Income	0.05	0.14	0.28	2.96	5.11	4.16	0.42	8.91	21	13
Other Income / (Expense), net	0.01	0.02	-0.14	-0.03	-15	-104	-197	-33	-0.73	-4.12
Income Tax Expense	-	-	-	0.00	0.00	1.85	0.35	0.67	2.13	1.16
Basic Earnings per Share	($8.03)	($3.22)	($3.68)	($2.34)	($4.90)	($4.59)	($8.84)	($6.15)	($4.45)	($1.60)
Weighted Average Basic Shares Outstanding	5.80M	8.43M	13.87M	54.40M	62.23M	75.16M	84.42M	106.11M	118.68M	123.91M
Diluted Earnings per Share	($8.03)	($3.22)	($3.68)	($2.34)	($4.90)	($4.59)	($8.84)	($6.15)	($4.45)	($1.60)
Weighted Average Diluted Shares Outstanding	5.80M	8.43M	13.87M	54.40M	62.23M	75.16M	84.42M	106.11M	118.68M	123.91M
Weighted Average Basic & Diluted Shares Outstanding	5.80M	8.43M	13.87M	54.40M	62.23M	75.16M	84.42M	111.29M	120.58M	125.52M

This table shows Apellis Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-191	-164	-178	-122	-140	-89	-66	-38	-57	-36
Consolidated Net Income / (Loss)	-191	-166	-178	-122	-140	-89	-66	-38	-57	-36
Net Income / (Loss) Continuing Operations	-191	-166	-178	-122	-140	-89	-66	-38	-57	-36
Total Pre-Tax Income	-191	-167	-177	-122	-140	-87	-66	-38	-57	-36
Total Operating Income	-153	-164	-175	-120	-137	-85	-62	-29	-47	-26
Total Gross Profit	22	23	45	95	110	146	172	200	197	213
Total Revenue	22	23	45	95	110	146	172	200	197	213
Operating Revenue	22	23	45	95	110	146	172	200	197	213
Total Operating Expenses	175	187	220	215	247	231	234	229	244	239
Selling, General & Admin Expense	78	84	102	111	146	142	130	128	122	121
Research & Development Expense	95	99	110	96	79	69	85	78	89	76
Other Operating Expenses / (Income)	0.00	-	7.81	8.38	22	20	20	23	34	41
Total Other Income / (Expense), net	-38	-3.12	-2.41	-1.40	-2.92	-2.64	-4.16	-8.10	-9.57	-9.90
Interest Expense	7.90	7.74	7.53	7.34	7.31	7.40	6.97	9.36	13	12
Interest & Investment Income	2.81	4.58	5.39	6.00	4.99	4.55	3.30	3.18	2.89	3.40
Other Income / (Expense), net	-33	0.04	-0.28	-0.06	-0.60	0.22	-0.50	-1.93	0.07	-1.77
Income Tax Expense	0.45	-1.47	0.28	0.19	0.23	1.42	0.17	0.11	0.59	0.29
Basic Earnings per Share	($1.75)	($1.52)	($1.56)	($1.02)	($1.17)	($0.70)	($0.54)	($0.30)	($0.46)	($0.30)
Weighted Average Basic Shares Outstanding	109.13M	106.11M	113.87M	119.32M	120.29M	118.68M	122.96M	123.90M	124.23M	123.91M
Diluted Earnings per Share	($1.75)	($1.52)	($1.56)	($1.02)	($1.17)	($0.70)	($0.54)	($0.30)	($0.46)	($0.30)
Weighted Average Diluted Shares Outstanding	109.13M	106.11M	113.87M	119.32M	120.29M	118.68M	122.96M	123.90M	124.23M	123.91M
Weighted Average Basic & Diluted Shares Outstanding	110.58M	111.29M	116.46M	117.74M	118.50M	120.58M	121.37M	121.77M	124.39M	125.52M

This table details how cash moves in and out of Apellis Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	22	-11	151	0.62	176	215	75	-89	-201	60
Net Cash From Operating Activities	-19	-26	-47	-131	-211	-160	-563	-514	-595	-88
Net Cash From Continuing Operating Activities	-19	-26	-47	-131	-211	-160	-563	-514	-595	-88
Net Income / (Loss) Continuing Operations	-47	-27	-51	-128	-305	-345	-746	-652	-529	-198
Consolidated Net Income / (Loss)	-47	-27	-51	-128	-305	-345	-746	-652	-529	-198
Depreciation Expense	-	-	0.00	0.00	0.24	0.64	1.38	1.55	1.78	1.80
Amortization Expense	0.00	0.00	0.03	0.65	2.70	16	1.08	0.46	0.30	1.56
Non-Cash Adjustments To Reconcile Net Income	26	1.49	5.42	7.73	37	148	274	152	132	125
Changes in Operating Assets and Liabilities, net	1.94	-0.37	-1.03	-12	53	20	-94	-16	-200	-18
Net Cash From Investing Activities	0.00	0.00	0.00	0.00	-1.69	-317	248	60	-0.67	-0.40
Net Cash From Continuing Investing Activities	0.00	0.00	0.00	0.00	-1.69	-317	248	60	-0.67	-0.40
Purchase of Property, Plant & Equipment	-	-	0.00	0.00	-1.69	-5.42	-1.10	-1.52	-0.77	-0.40
Purchase of Investments	-	-	-	0.00	0.00	-879	-171	-332	0.00	0.00
Sale of Property, Plant & Equipment	-	-	-	-	-	-	0.00	0.00	0.10	0.00
Sale and/or Maturity of Investments	-	-	-	0.00	0.00	568	420	393	0.00	0.00
Net Cash From Financing Activities	41	15	197	132	389	692	392	366	394	149
Net Cash From Continuing Financing Activities	41	15	197	132	389	692	392	366	394	149
Repayment of Debt	-	-	0.00	0.00	184	323	-	0.00	0.00	-7.21
Issuance of Debt	0.00	0.00	26	-	-	-	-	0.00	0.00	365
Issuance of Common Equity	0.00	0.00	150	131	110	383	383	384	390	4.51
Other Financing Activities, net	0.00	0.00	0.68	0.73	95	-14	8.90	-19	4.73	-214
Effect of Exchange Rate Changes	-	0.00	0.00	-0.04	0.00	0.36	-2.02	-0.49	0.14	-0.66
Cash Interest Paid	-	0.00	0.13	1.82	0.99	13	10	5.00	3.29	29
Cash Income Taxes Paid	-	-	-	-	-	1.65	0.05	4.92	0.00	1.65

This table details how cash moves in and out of Apellis Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-20	-32	213	-149	-164	-101	-25	34	37	14
Net Cash From Operating Activities	-154	-141	-178	-150	-169	-98	-133	-8.34	34	19
Net Cash From Continuing Operating Activities	-154	-141	-178	-150	-169	-98	-133	-8.46	34	19
Net Income / (Loss) Continuing Operations	-191	-166	-178	-122	-140	-89	-66	-38	-57	-36
Consolidated Net Income / (Loss)	-191	-166	-178	-122	-140	-89	-66	-38	-57	-36
Depreciation Expense	0.40	0.39	0.42	0.43	0.46	0.48	0.44	0.45	0.46	0.45
Amortization Expense	0.05	0.18	0.00	0.15	0.08	0.08	0.08	0.24	0.66	0.59
Non-Cash Adjustments To Reconcile Net Income	64	31	35	36	28	33	36	35	27	26
Changes in Operating Assets and Liabilities, net	-28	-6.42	-36	-64	-58	-43	-103	-6.29	63	28
Net Cash From Investing Activities	125	124	-0.26	-0.37	-0.05	0.00	-0.29	-0.09	-	-0.02
Net Cash From Continuing Investing Activities	125	124	-0.26	-0.37	-0.05	0.00	-0.29	-0.09	-	-0.02
Purchase of Property, Plant & Equipment	-0.20	-0.85	-0.26	-0.37	-0.05	-0.10	-0.29	-0.09	-	-0.02
Net Cash From Financing Activities	9.64	-16	391	1.56	5.75	-3.91	108	42	2.54	-4.00
Net Cash From Continuing Financing Activities	9.64	-16	391	1.56	5.75	-3.91	108	42	2.54	-4.00
Repayment of Debt	-	-	-	-	-	-	-	-	-	-5.63
Issuance of Common Equity	-	1.71	384	3.75	-	1.62	0.00	3.19	-	1.32
Other Financing Activities, net	9.64	-18	6.72	-2.19	5.75	-5.54	108	-325	2.54	0.31
Effect of Exchange Rate Changes	-0.31	0.19	0.06	-0.05	-0.46	0.58	-0.21	0.34	0.17	-0.97
Cash Interest Paid	1.64	-	1.64	-	1.64	-	1.64	5.31	12	9.92
Cash Income Taxes Paid	-	4.76	0.25	0.13	0.19	-0.58	0.00	-	0.60	1.05

This table presents Apellis Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	27	182	204	389	961	882	760	789	885
Total Current Assets	27	182	202	373	917	824	720	766	789
Cash & Equivalents	25	176	176	352	566	640	552	351	411
Restricted Cash	-	-	-	0.00	1.27	1.56	1.27	1.11	1.32
Accounts Receivable	-	-	-	-	0.00	10	7.73	206	265
Inventories, net	-	-	-	-	0.00	16	86	146	81
Prepaid Expenses	1.13	5.06	24	20	11	25	36	39	18
Other Current Assets	1.37	1.31	1.84	1.31	27	71	37	22	12
Plant, Property, & Equipment, net	0.00	0.00	0.98	1.66	6.80	6.18	6.15	4.35	2.95
Total Noncurrent Assets	0.06	0.12	0.12	14	37	52	35	18	93
Other Noncurrent Operating Assets	-	-	0.12	14	37	52	35	18	93
Total Liabilities & Shareholders' Equity	27	182	204	389	961	882	760	789	885
Total Liabilities	3.64	33	43	355	756	683	590	594	657
Total Current Liabilities	3.64	6.55	17	66	128	132	168	248	186
Accounts Payable	2.55	3.66	10	8.36	8.48	17	37	38	39
Accrued Expenses	1.09	2.89	5.10	55	112	103	95	128	140
Current Deferred Revenue	-	-	-	-	-	-	-	0.00	0.00
Other Current Liabilities	-	-	0.00	2.61	7.92	12	35	82	6.75
Total Noncurrent Liabilities	0.00	26	26	289	628	551	423	347	471
Long-Term Debt	0.00	26	25	143	359	189	93	93	453
Other Noncurrent Operating Liabilities	-	-	0.16	147	269	362	330	254	18
Commitments & Contingencies	-	-	-	0.00	0.00	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	24	149	161	34	205	199	170	195	229
Total Preferred & Common Equity	24	149	161	34	205	199	170	195	229
Preferred Stock	92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-68	149	161	34	205	199	170	195	229
Common Stock	30	298	438	616	1,131	1,857	2,480	3,036	3,267
Retained Earnings	-98	-149	-277	-581	-926	-1,657	-2,309	-2,837	-3,035
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-0.12	-0.15	-0.12	-2.09	-0.88	-3.54	-3.31

This table presents Apellis Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	873	979	916	818	832	904	902
Total Current Assets	832	954	893	797	811	860	834
Cash & Equivalents	584	765	616	452	326	360	397
Restricted Cash	1.26	1.28	1.09	1.09	1.10	1.34	1.37
Accounts Receivable	8.09	32	111	169	268	304	279
Inventories, net	60	85	103	99	161	153	121
Prepaid Expenses	30	37	34	45	43	29	24
Other Current Assets	24	34	27	31	12	12	12
Plant, Property, & Equipment, net	5.68	5.97	5.34	4.79	4.20	3.84	3.38
Total Noncurrent Assets	35	19	18	17	16	41	65
Other Noncurrent Operating Assets	35	19	18	17	16	41	65
Total Liabilities & Shareholders' Equity	873	979	916	818	832	904	902
Total Liabilities	565	567	570	586	565	640	665
Total Current Liabilities	115	139	175	186	215	169	191
Accounts Payable	14	31	28	18	27	38	43
Accrued Expenses	80	71	98	117	101	123	140
Current Deferred Revenue	-	-	-	-	3.56	1.90	1.90
Other Current Liabilities	22	36	50	50	84	6.21	6.79
Total Noncurrent Liabilities	450	428	395	400	350	471	473
Long-Term Debt	93	93	93	93	93	457	452
Other Noncurrent Operating Liabilities	357	335	302	307	257	14	21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	307	412	345	232	267	264	237
Total Preferred & Common Equity	307	412	345	232	267	264	237
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	307	412	345	232	267	264	237
Common Stock	2,453	2,900	2,955	2,982	3,174	3,209	3,239
Retained Earnings	-2,143	-2,487	-2,609	-2,749	-2,904	-2,942	-2,999
Accumulated Other Comprehensive Income / (Loss)	-3.03	-0.78	-0.80	-1.07	-3.53	-3.36	-3.14

This table displays calculated financial ratios and metrics derived from Apellis Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-73.44%	13.31%	425.83%	97.02%
EBITDA Growth	0.00%	41.46%	-86.66%	-150.17%	-135.74%	-0.26%	-142.88%	14.40%	17.54%	67.86%
EBIT Growth	0.00%	41.46%	-86.75%	-151.33%	-136.83%	-4.69%	-131.10%	14.41%	17.47%	67.35%
NOPAT Growth	0.00%	41.42%	-86.08%	-151.98%	-125.14%	25.79%	-150.92%	-10.88%	13.03%	68.10%
Net Income Growth	0.00%	41.69%	-88.04%	-149.97%	-138.98%	-13.18%	-116.41%	12.62%	18.94%	62.57%
EPS Growth	0.00%	59.90%	-14.29%	36.41%	-109.40%	6.33%	-92.59%	30.43%	27.64%	64.04%
Operating Cash Flow Growth	0.00%	-37.90%	-79.19%	-181.66%	-60.88%	23.99%	-250.88%	8.77%	-15.76%	85.23%
Free Cash Flow Firm Growth	0.00%	0.00%	-103.12%	-178.11%	85.54%	36.82%	-3,961.34%	-16.92%	-33.51%	23.60%
Invested Capital Growth	0.00%	0.00%	83.93%	6,549.17%	-1,591.08%	-80.11%	0.35%	7.62%	77.71%	515.10%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	38,699.69%	-74.03%	-33.28%	45.34%	9.25%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-17.43%	-31.34%	40.34%	-48.59%	-3.19%	13.44%	25.57%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-17.45%	-32.10%	38.70%	-46.91%	-3.19%	13.38%	25.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-17.66%	-31.35%	52.48%	-69.30%	-14.36%	13.33%	26.13%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-17.11%	-33.42%	35.70%	-43.49%	-2.85%	12.77%	20.88%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-58.11%	-30.67%	38.47%	-41.21%	0.00%	15.56%	20.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-23.90%	-28.30%	-21.66%	58.26%	-82.45%	-5.82%	6.72%	57.16%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-667.47%	95.34%	-96.15%	-24.41%	1.91%	22.01%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	420.44%	-13.89%	-16.95%	-4.95%	6.22%	49.53%	-7.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-120.03%	-1,097.79%	-829.32%	-130.05%	-21.21%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-85.27%	-805.67%	-788.38%	-130.39%	-21.11%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-126.58%	-1,101.48%	-831.99%	-130.57%	-21.64%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-137.59%	-1,121.27%	-864.70%	-133.29%	-25.32%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.54%	100.05%	100.10%	100.40%	100.59%
Interest Burden Percent	99.89%	99.50%	100.19%	99.65%	100.55%	108.12%	101.75%	103.82%	101.67%	116.33%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-113.21%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-37.99%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	19.67%
Return on Equity (ROE)	0.00%	-114.00%	-59.06%	-82.28%	-312.20%	-288.86%	-370.20%	-353.93%	-290.14%	-93.55%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-863.71%	0.00%	0.00%	0.00%	0.00%	0.00%	-167.06%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-47.01%	-79.59%	-76.43%	-66.86%	-20.21%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	-51.10%	-81.02%	-79.44%	-68.26%	-23.64%
Return on Common Equity (ROCE)	0.00%	327.03%	-27.58%	-82.28%	-312.20%	-288.86%	-370.20%	-353.93%	-290.14%	-93.55%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-114.00%	-34.25%	-79.21%	-890.20%	-168.60%	-375.69%	-383.92%	-271.76%	-86.58%
Net Operating Profit after Tax (NOPAT)	-33	-19	-36	-90	-202	-150	-375	-416	-362	-115
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-59.69%	-563.97%	-551.87%	-91.27%	-14.78%
Net Nonoperating Expense Percent (NNEP)	0.00%	-64.40%	-17.78%	-25.44%	-57.49%	-53.53%	-71.81%	-48.48%	-46.32%	-75.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-158.50%	-125.88%	-16.95%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	55.62%	265.57%	367.48%	126.28%	64.13%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	119.66%	519.61%	513.43%	89.36%	41.92%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	185.27%	905.67%	888.38%	230.39%	121.11%
Earnings before Interest and Taxes (EBIT)	-47	-27	-51	-128	-303	-317	-733	-628	-518	-169
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-47	-27	-51	-127	-300	-301	-731	-625	-516	-166
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	7.33	4.61	57.15	21.18	20.78	33.66	36.47	17.37
Price to Tangible Book Value (P/TBV)	0.00	0.00	7.33	4.61	57.15	21.18	20.78	33.66	36.47	17.37
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	17.28	62.01	75.81	17.89	5.08
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	50.44	0.00	0.00	0.00	0.00	0.00	14.92
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	15.21	54.30	69.71	17.23	5.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.18	0.17	4.17	1.75	0.95	0.55	0.48	1.98
Long-Term Debt to Equity	0.00	0.00	0.18	0.16	4.17	1.75	0.95	0.55	0.48	1.98
Financial Leverage	0.00	-1.05	-1.01	-0.96	-1.84	-3.06	-2.56	-2.64	-1.97	-0.52
Leverage Ratio	0.00	1.15	1.21	1.24	3.04	5.65	4.57	4.46	4.25	3.96
Compound Leverage Factor	0.00	1.15	1.22	1.24	3.05	6.11	4.65	4.63	4.32	4.60
Debt to Total Capital	0.00%	0.00%	15.05%	14.38%	80.64%	63.69%	48.76%	35.31%	32.35%	66.46%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	15.05%	13.50%	80.64%	63.69%	48.76%	35.31%	32.35%	66.46%
Preferred Equity to Total Capital	0.00%	386.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-286.88%	84.95%	85.62%	19.36%	36.31%	51.24%	64.69%	67.65%	33.54%
Debt to EBITDA	0.00	0.00	-0.52	-0.21	-0.48	-1.19	-0.26	-0.15	-0.18	-2.73
Net Debt to EBITDA	0.00	0.00	2.93	1.17	0.70	1.73	0.70	0.74	0.50	-0.24
Long-Term Debt to EBITDA	0.00	0.00	-0.52	-0.20	-0.48	-1.19	-0.26	-0.15	-0.18	-2.73
Debt to NOPAT	0.00	0.00	-0.74	-0.30	-0.71	-2.40	-0.50	-0.22	-0.26	-3.92
Net Debt to NOPAT	0.00	0.00	4.20	1.67	1.04	3.48	1.37	1.11	0.72	-0.35
Long-Term Debt to NOPAT	0.00	0.00	-0.74	-0.28	-0.71	-2.40	-0.50	-0.22	-0.26	-3.92
Altman Z-Score	0.00	0.00	18.83	7.57	-0.41	2.24	-0.73	-0.19	1.25	-0.10
Noncontrolling Interest Sharing Ratio	0.00%	386.88%	53.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	7.52	27.77	11.89	5.67	7.15	6.25	4.29	3.10	4.25
Quick Ratio	0.00	6.83	26.80	10.35	5.35	6.84	5.39	3.34	2.25	3.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-18	-36	-101	-15	-9.27	-376	-440	-588	-449
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	-12,471.06%	-2,959.94%	-51,054.03%	-33,710.30%	-88,239.61%	-21,802.98%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-97.37	-40.38	-2.16	-0.31	-28.43	-13.49	-19.87	-11.12
Operating Cash Flow to Interest Expense	0.00	0.00	-124.34	-52.22	-31.11	-5.36	-42.53	-15.75	-20.11	-2.18
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-124.34	-52.22	-31.36	-5.54	-42.61	-15.79	-20.13	-2.19
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.37	0.07	0.09	0.51	0.93
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.46	3.70	3.32
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	59.27	10.26	12.24	75.59	214.16
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.14	98.55	110.10
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.14	98.55	110.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-1.13	-0.18	12	-175	-316	-314	-290	-65	269
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	-1.02	-0.21	-0.25	-2.23	7.66
Increase / (Decrease) in Invested Capital	0.00	-1.13	0.95	12	-187	-140	1.10	24	226	334
Enterprise Value (EV)	0.00	0.00	943	593	1,747	3,812	3,614	5,258	6,834	4,010
Market Capitalization	0.00	0.00	1,092	742	1,956	4,332	4,127	5,718	7,093	3,969
Book Value per Share	$0.00	($8.10)	$2.96	$2.86	$0.54	$2.70	$2.28	$1.54	$1.64	$1.84
Tangible Book Value per Share	$0.00	($8.10)	$2.96	$2.86	$0.54	$2.70	$2.28	$1.54	$1.64	$1.84
Total Capital	0.00	24	175	188	177	563	388	263	288	681
Total Debt	0.00	0.00	26	27	143	359	189	93	93	453
Total Long-Term Debt	0.00	0.00	26	25	143	359	189	93	93	453
Net Debt	0.00	-25	-149	-149	-209	-520	-513	-460	-259	40
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	1.69	5.42	1.10	1.52	0.67	0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-1.13	-0.18	11	-45	-90	-9.91	-1.16	166	191
Debt-free Net Working Capital (DFNWC)	0.00	24	175	187	307	789	692	552	519	603
Net Working Capital (NWC)	0.00	24	175	185	307	789	692	552	519	603
Net Nonoperating Expense (NNE)	14	8.03	15	38	103	195	371	236	167	82
Net Nonoperating Obligations (NNO)	0.00	-25	-149	-149	-209	-520	-513	-460	-259	40
Total Depreciation and Amortization (D&A)	0.00	0.00	0.03	0.65	2.94	16	2.46	2.01	2.08	3.36
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	-35.93%	-14.89%	-1.54%	41.97%	24.42%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	314.73%	1,039.92%	731.77%	130.80%	77.23%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	314.73%	1,039.92%	731.77%	130.80%	77.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($3.68)	($2.34)	($4.90)	($4.59)	($8.84)	($6.15)	$0.00	($1.60)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	50.37M	56.28M	75.32M	80.38M	97.73M	106.11M	0.00	123.91M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($3.68)	($2.34)	($4.90)	($4.59)	($8.84)	($6.15)	$0.00	($1.60)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	50.37M	56.28M	75.32M	80.38M	97.73M	106.11M	0.00	123.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($3.68)	($2.34)	($4.90)	($4.59)	($8.84)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	13.87M	54.40M	62.23M	75.16M	84.42M	111.29M	0.00	125.52M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-19	-36	-90	-202	-150	-375	-416	-362	-115
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-59.69%	-563.97%	-551.87%	-91.27%	-14.78%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-136.86%	-1,120.75%	-863.81%	-132.76%	-25.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-135.85	-50.92	-44.66	-10.60	-55.37	-19.23	-17.51	-4.19
NOPAT to Interest Expense	0.00	0.00	-94.83	-35.63	-29.71	-5.00	-28.35	-12.76	-12.24	-2.86
EBIT Less CapEx to Interest Expense	0.00	0.00	-135.85	-50.92	-44.90	-10.78	-55.46	-19.28	-17.53	-4.20
NOPAT Less CapEx to Interest Expense	0.00	0.00	-94.83	-35.63	-29.96	-5.18	-28.43	-12.80	-12.26	-2.87
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.20%	0.00%	0.00%	-0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Apellis Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	290.37%	-62.41%	211.84%	481.85%	400.54%	545.89%	284.26%	110.26%	78.29%	45.19%
EBITDA Growth	4.01%	-13.44%	-35.84%	18.96%	25.98%	48.76%	64.52%	74.42%	66.39%	67.88%
EBIT Growth	3.98%	-13.42%	-35.64%	18.84%	25.87%	48.60%	64.31%	73.97%	65.71%	66.87%
NOPAT Growth	-19.49%	-83.50%	-35.73%	18.96%	10.37%	48.48%	64.54%	75.55%	65.51%	69.04%
Net Income Growth	2.20%	-12.21%	-27.96%	21.76%	26.68%	46.64%	62.64%	69.14%	59.04%	58.96%
EPS Growth	23.25%	0.00%	-9.86%	30.14%	33.14%	53.95%	65.38%	70.59%	60.68%	57.14%
Operating Cash Flow Growth	8.43%	-25.11%	-59.21%	-40.30%	-9.50%	30.46%	25.13%	94.45%	120.17%	119.78%
Free Cash Flow Firm Growth	-62.03%	-117.95%	-183.63%	-82.18%	-186.25%	-105.25%	-91.21%	-137.62%	-63.11%	-23.50%
Invested Capital Growth	-3.39%	7.62%	17.13%	45.79%	58.59%	77.71%	112.53%	301.11%	326.96%	515.10%
Revenue Q/Q Growth	35.13%	2.75%	97.88%	111.77%	16.25%	32.59%	17.73%	15.88%	-1.43%	7.97%
EBITDA Q/Q Growth	-25.20%	11.78%	-6.80%	31.44%	-14.35%	38.93%	25.88%	50.57%	-50.24%	41.65%
EBIT Q/Q Growth	-25.09%	11.69%	-6.73%	31.28%	-14.26%	38.77%	25.76%	49.88%	-50.50%	40.84%
NOPAT Q/Q Growth	-2.90%	-7.27%	-6.72%	31.21%	-13.82%	38.34%	26.54%	52.58%	-60.58%	44.66%
Net Income Q/Q Growth	-22.63%	13.22%	-7.10%	31.35%	-14.91%	36.84%	25.01%	43.31%	-52.55%	36.72%
EPS Q/Q Growth	-19.86%	13.14%	-2.63%	34.62%	-14.71%	40.17%	22.86%	44.44%	-53.33%	34.78%
Operating Cash Flow Q/Q Growth	-44.28%	8.85%	-26.20%	15.46%	-12.61%	42.11%	-35.87%	93.73%	508.87%	-43.22%
Free Cash Flow Firm Q/Q Growth	25.05%	-43.22%	-27.22%	-33.41%	-17.76%	-2.69%	-18.52%	-65.79%	19.17%	22.25%
Invested Capital Q/Q Growth	6.24%	6.22%	10.00%	31.51%	28.36%	49.53%	150.60%	999.28%	-19.16%	-7.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-840.03%	-721.20%	-390.09%	-126.29%	-124.23%	-57.22%	-36.02%	-15.36%	-23.42%	-12.66%
Operating Margin	-693.41%	-723.88%	-390.41%	-126.82%	-124.17%	-57.74%	-36.03%	-14.74%	-24.02%	-12.31%
EBIT Margin	-842.08%	-723.70%	-391.03%	-126.89%	-124.71%	-57.59%	-36.32%	-15.71%	-23.99%	-13.14%
Profit (Net Income) Margin	-867.20%	-732.43%	-396.42%	-128.50%	-127.03%	-60.51%	-38.55%	-18.86%	-29.19%	-17.11%
Tax Burden Percent	100.23%	99.12%	100.16%	100.16%	100.17%	101.63%	100.26%	100.30%	101.04%	100.79%
Interest Burden Percent	102.74%	102.10%	101.22%	101.11%	101.69%	103.38%	105.85%	119.69%	120.43%	129.13%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-71.69%	-147.69%	-66.02%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-63.74%	-131.80%	-49.55%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	44.81%	86.07%	25.65%
Return on Equity (ROE)	-507.11%	-353.93%	-158.06%	-193.31%	-224.59%	-290.14%	-122.94%	-26.88%	-61.62%	-40.36%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,761.58%	-210.59%	-197.76%	-167.06%
Operating Return on Assets (OROA)	-136.13%	-66.48%	-38.97%	-24.42%	-40.25%	-29.49%	-21.02%	-10.85%	-19.95%	-12.27%
Return on Assets (ROA)	-140.19%	-67.29%	-39.51%	-24.73%	-40.99%	-30.99%	-22.31%	-13.03%	-24.27%	-15.97%
Return on Common Equity (ROCE)	-507.11%	-353.93%	-158.06%	-193.31%	-224.59%	-290.14%	-122.94%	-26.88%	-61.62%	-40.36%
Return on Equity Simple (ROE_SIMPLE)	-206.27%	0.00%	-167.67%	-190.23%	-260.92%	0.00%	-156.47%	-125.94%	-105.47%	0.00%
Net Operating Profit after Tax (NOPAT)	-107	-115	-123	-84	-96	-59	-43	-21	-33	-18
NOPAT Margin	-485.39%	-506.72%	-273.29%	-88.78%	-86.92%	-40.42%	-25.22%	-10.32%	-16.81%	-8.62%
Net Nonoperating Expense Percent (NNEP)	-19.60%	-10.51%	-7.61%	-6.35%	-9.06%	-8.18%	-5.06%	-7.95%	-15.89%	-16.47%
Return On Investment Capital (ROIC_SIMPLE)	-	-43.73%	-	-	-	-20.57%	-	-	-	-2.69%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	355.49%	372.27%	227.65%	117.27%	131.93%	96.81%	75.15%	64.14%	61.97%	57.16%
R&D to Revenue	431.66%	438.70%	245.34%	100.73%	71.94%	47.33%	49.15%	39.04%	45.00%	35.93%
Operating Expenses to Revenue	793.41%	823.88%	490.41%	226.82%	224.17%	157.74%	136.03%	114.74%	124.02%	112.31%
Earnings before Interest and Taxes (EBIT)	-186	-164	-175	-121	-138	-84	-63	-31	-47	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-185	-163	-175	-120	-137	-84	-62	-31	-46	-27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	24.41	33.66	17.81	30.72	19.28	36.47	26.58	17.61	14.81	17.37
Price to Tangible Book Value (P/TBV)	24.41	33.66	17.81	30.72	19.28	36.47	26.58	17.61	14.81	17.37
Price to Revenue (P/Rev)	66.38	75.81	69.33	57.49	16.41	17.89	13.52	7.40	4.91	5.08
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	209.22	13.19	12.25	14.92
Enterprise Value to Revenue (EV/Rev)	60.92	69.71	62.97	54.65	15.09	17.23	13.08	7.56	4.99	5.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.30	0.55	0.23	0.27	0.40	0.48	0.35	1.73	1.91	1.98
Long-Term Debt to Equity	0.30	0.55	0.23	0.27	0.40	0.48	0.35	1.73	1.91	1.98
Financial Leverage	-3.44	-2.64	-1.66	-1.75	-1.81	-1.97	-1.34	-0.70	-0.65	-0.52
Leverage Ratio	5.59	4.46	2.43	2.82	3.13	4.25	2.67	2.99	3.66	3.96
Compound Leverage Factor	5.75	4.55	2.46	2.85	3.19	4.39	2.82	3.57	4.41	5.11
Debt to Total Capital	23.16%	35.31%	18.38%	21.19%	28.58%	32.35%	25.88%	63.37%	65.60%	66.46%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	23.16%	35.31%	18.38%	21.19%	28.58%	32.35%	25.88%	63.37%	65.60%	66.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	76.84%	64.69%	81.62%	78.81%	71.42%	67.65%	74.12%	36.63%	34.40%	33.54%
Debt to EBITDA	-0.15	-0.15	-0.14	-0.14	-0.16	-0.18	-0.23	-1.46	-2.03	-2.73
Net Debt to EBITDA	1.02	0.74	1.00	0.81	0.61	0.50	0.58	-0.31	-0.24	-0.24
Long-Term Debt to EBITDA	-0.15	-0.15	-0.14	-0.14	-0.16	-0.18	-0.23	-1.46	-2.03	-2.73
Debt to NOPAT	-0.25	-0.22	-0.21	-0.22	-0.22	-0.26	-0.33	-2.09	-2.89	-3.92
Net Debt to NOPAT	1.70	1.11	1.50	1.22	0.86	0.72	0.83	-0.44	-0.35	-0.35
Long-Term Debt to NOPAT	-0.25	-0.22	-0.21	-0.22	-0.22	-0.26	-0.33	-2.09	-2.89	-3.92
Altman Z-Score	4.94	1.82	4.73	7.88	0.56	3.07	3.88	1.31	-0.01	0.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.21	4.29	6.88	5.11	4.29	3.10	3.77	5.08	4.36	4.25
Quick Ratio	6.21	3.34	5.75	4.16	3.35	2.25	2.76	3.93	3.53	3.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-97	-139	-177	-236	-277	-285	-338	-560	-452	-352
Operating Cash Flow to CapEx	-78,784.18%	-16,538.66%	-68,579.15%	-40,364.25%	-359,755.32%	-103,026.32%	-45,386.69%	-9,265.56%	0.00%	96,800.00%
Free Cash Flow to Firm to Interest Expense	-12.26	-17.94	-23.45	-32.09	-37.95	-38.49	-48.46	-59.81	-36.11	-30.51
Operating Cash Flow to Interest Expense	-19.54	-18.19	-23.59	-20.45	-23.13	-13.22	-19.09	-0.89	2.72	1.68
Operating Cash Flow Less CapEx to Interest Expense	-19.56	-18.30	-23.63	-20.51	-23.14	-13.24	-19.13	-0.90	2.72	1.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.16	0.09	0.10	0.19	0.32	0.51	0.58	0.69	0.83	0.93
Accounts Receivable Turnover	19.47	8.46	5.60	3.12	3.08	3.70	3.50	3.03	3.19	3.32
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	18.55	12.24	17.86	32.86	52.12	75.59	103.14	137.07	175.11	214.16
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	18.75	43.14	65.21	117.13	118.61	98.55	104.24	120.55	114.38	110.10
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	18.75	43.14	65.21	117.13	118.61	98.55	104.24	120.55	114.38	110.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-310	-290	-261	-179	-128	-65	33	360	291	269
Invested Capital Turnover	-0.37	-0.25	-0.37	-0.72	-1.25	-2.23	-4.58	6.95	8.78	7.66
Increase / (Decrease) in Invested Capital	-10	24	54	151	181	226	294	539	419	334
Enterprise Value (EV)	6,887	5,258	6,667	10,085	4,118	6,834	6,854	4,751	3,566	4,010
Market Capitalization	7,504	5,718	7,341	10,609	4,479	7,093	7,088	4,656	3,512	3,969
Book Value per Share	$2.80	$1.54	$3.70	$2.97	$1.97	$1.64	$2.21	$2.18	$1.95	$1.84
Tangible Book Value per Share	$2.80	$1.54	$3.70	$2.97	$1.97	$1.64	$2.21	$2.18	$1.95	$1.84
Total Capital	400	263	505	438	325	288	360	722	689	681
Total Debt	93	93	93	93	93	93	93	457	452	453
Total Long-Term Debt	93	93	93	93	93	93	93	457	452	453
Net Debt	-617	-460	-674	-524	-361	-259	-234	96	54	40
Capital Expenditures (CapEx)	0.20	0.85	0.26	0.37	0.05	0.10	0.29	0.09	0.00	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.68	-1.16	49	101	158	166	269	329	244	191
Debt-free Net Working Capital (DFNWC)	716	552	816	718	611	519	596	691	643	603
Net Working Capital (NWC)	716	552	816	718	611	519	596	691	643	603
Net Nonoperating Expense (NNE)	84	51	55	38	44	29	23	17	24	18
Net Nonoperating Obligations (NNO)	-617	-460	-674	-524	-361	-259	-234	96	54	40
Total Depreciation and Amortization (D&A)	0.45	0.57	0.42	0.57	0.54	0.55	0.52	0.69	1.12	1.03
Debt-free, Cash-free Net Working Capital to Revenue	5.91%	-1.54%	46.51%	54.46%	57.77%	41.97%	51.35%	52.38%	34.17%	24.42%
Debt-free Net Working Capital to Revenue	633.79%	731.77%	770.27%	389.01%	223.96%	130.80%	113.75%	109.86%	89.85%	77.23%
Net Working Capital to Revenue	633.79%	731.77%	770.27%	389.01%	223.96%	130.80%	113.75%	109.86%	89.85%	77.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.75)	($1.52)	($1.56)	($1.02)	($1.17)	($0.70)	($0.54)	($0.30)	($0.46)	($0.30)
Adjusted Weighted Average Basic Shares Outstanding	109.13M	106.11M	113.87M	119.32M	120.29M	118.68M	122.96M	123.90M	124.23M	123.91M
Adjusted Diluted Earnings per Share	($1.75)	($1.52)	($1.56)	($1.02)	($1.17)	($0.70)	($0.54)	($0.30)	($0.46)	($0.30)
Adjusted Weighted Average Diluted Shares Outstanding	109.13M	106.11M	113.87M	119.32M	120.29M	118.68M	122.96M	123.90M	124.23M	123.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	110.58M	111.29M	116.46M	117.74M	118.50M	120.58M	121.37M	121.77M	124.39M	125.52M
Normalized Net Operating Profit after Tax (NOPAT)	-107	-115	-123	-84	-96	-59	-43	-21	-33	-18
Normalized NOPAT Margin	-485.39%	-506.72%	-273.29%	-88.78%	-86.92%	-40.42%	-25.22%	-10.32%	-16.81%	-8.62%
Pre Tax Income Margin	-865.18%	-738.92%	-395.79%	-128.30%	-126.82%	-59.54%	-38.45%	-18.80%	-28.88%	-16.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-23.50	-21.20	-23.29	-16.42	-18.83	-11.39	-8.98	-3.35	-3.77	-2.42
NOPAT to Interest Expense	-13.55	-14.84	-16.28	-11.48	-13.13	-7.99	-6.24	-2.20	-2.64	-1.59
EBIT Less CapEx to Interest Expense	-23.53	-21.31	-23.33	-16.47	-18.84	-11.40	-9.03	-3.36	-3.77	-2.42
NOPAT Less CapEx to Interest Expense	-13.57	-14.95	-16.31	-11.54	-13.13	-8.01	-6.28	-2.21	-2.64	-1.59
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Apellis Pharmaceuticals' Financials

When does Apellis Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Apellis Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Apellis Pharmaceuticals' net income changed over the last 9 years?

Apellis Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$197.88 million in 2024, rising from -$46.52 million in 2015. The previous period was -$528.63 million in 2023.

What is Apellis Pharmaceuticals's operating income?

Apellis Pharmaceuticals's total operating income in 2024 was -$164.98 million, based on the following breakdown:

Total Gross Profit: $781.37 million
Total Operating Expenses: $946.35 million

How has Apellis Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Apellis Pharmaceuticals' total revenue changed from $0.00 in 2015 to $781.37 million in 2024, a change of 78,136,700,000.0%.

How much debt does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals' total liabilities were at $656.51 million at the end of 2024, a 10.5% increase from 2023, and a 17,941.3% increase since 2016.

How much cash does Apellis Pharmaceuticals have?

In the past 8 years, Apellis Pharmaceuticals' cash and equivalents has ranged from $24.86 million in 2016 to $640.19 million in 2021, and is currently $411.29 million as of their latest financial filing in 2024.

How has Apellis Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Apellis Pharmaceuticals' book value per share changed from 0.00 in 2015 to 1.84 in 2024, a change of 183.7%.

Related Companies

This page (NASDAQ:APLS) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apellis Pharmaceuticals (APLS) Financials

Frequently Asked Questions About Apellis Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apellis Pharmaceuticals (APLS) Financials

Annual Income Statements for Apellis Pharmaceuticals

Quarterly Income Statements for Apellis Pharmaceuticals

Annual Cash Flow Statements for Apellis Pharmaceuticals

Quarterly Cash Flow Statements for Apellis Pharmaceuticals

Annual Balance Sheets for Apellis Pharmaceuticals

Quarterly Balance Sheets for Apellis Pharmaceuticals

Annual Metrics and Ratios for Apellis Pharmaceuticals

Quarterly Metrics and Ratios for Apellis Pharmaceuticals

Frequently Asked Questions About Apellis Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools